Synonyms: AMG-899 | DEZ-001 | TA-8995 | TA8995
Compound class:
Synthetic organic
Comment: Obicetrapib is a clinical lead, orally bioavailable, small molecule, cholesterol ester transfer protein (CETP; P11597) inhibitor [1]. It was developed as a treament for dyslipidemia. Agents of the CETP inhibitor class are proposed to increase HDL cholesterol, lower LDL cholesterol, and enhance reverse cholesterol transport, as a mechanism to reduce the risks of elevated cholesterol on atherosclerosis. Prior to the re-launching of trials involving obicetrapib by NewAmsterdam Pharma, no CETP inhibitor had demonstrated sufficient safety and/or efficacy in a clinical study to warrant continued development [2].
|
|
Classification | |
Compound class | Synthetic organic |
IUPAC Name |
4-[2-[[3,5-bis(trifluoromethyl)phenyl]methyl-[(2R,4S)-1-ethoxycarbonyl-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2H-quinolin-4-yl]amino]pyrimidin-5-yl]oxybutanoic acid |
International Nonproprietary Names | |
INN number | INN |
9979 | obicetrapib |
Synonyms |
AMG-899 | DEZ-001 | TA-8995 | TA8995 |
Database Links | |
CAS Registry No. | 866399-87-3 (source: WHO INN record) |
ChEMBL Ligand | CHEMBL3785197 |
DrugBank Ligand | DB14890 |
GtoPdb PubChem SID | 472319325 |
PubChem CID | 11498596 |
Search Google for chemical match using the InChIKey | NRWORBQAOQVYBJ-GJZUVCINSA-N |
Search Google for chemicals with the same backbone | NRWORBQAOQVYBJ |
Search PubMed clinical trials | obicetrapib |
Search PubMed titles | obicetrapib |
Search PubMed titles/abstracts | obicetrapib |
UniChem Compound Search for chemical match using the InChIKey | NRWORBQAOQVYBJ-GJZUVCINSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | NRWORBQAOQVYBJ-GJZUVCINSA-N |